Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 405-407

  Remme, Willem J ^a  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

ACE inhibitor; Coronary artery disease; EUROPA; PEACE; Secondary prevention

Indexed keywords

ANGIOTENSIN II; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE;

EID: 36849024567     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6071-x     Document Type: Editorial

References (26)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
2. Gomma AH, Fox KM, on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001;15:169-79
3. The European Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (EUROPA). Lancet 2003;362:782-8.
4. Deckers JW, Goedhart DM, Boersma E, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796-801
5. Remme WJ. Prevention of cardiovascular events by perindopril in patients with stable coronary disease does not depend on blood pressure and its reduction-results from the EUROPA study. Circulation 2004;110:III628 (abstract)
6. Bots ML, Remme WJ, Lüscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007;21:269-79
7. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003;41:1373-9
8. Matsumoto K, Morishita R, Moriguchi A, Tomita N, Aoki M, Sakonjo H, et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 2001;37:270-4
9. Antoni I, Lerebours G, Nitenberg A. Angiotensin converting enzyme inhibition restores flow-dependent and cold-pressure test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22
10. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246-53
11. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8
12. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996;23:530-2
13. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-6
14. Thybo NK, Korsgaard N, Eriksen S, et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension 1994;23:659-66
15. Braunwald E, Domanski MJ, Fowler SE, et al. on behalf of the PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68
16. Ferrari R. ACE inhibition for secondary prevention of cardiovascular events-should we change our recommendation after PEACE? Cardiovasc Drugs Ther 2006;20:11-2
17. Voors AA, van Veldhuisen DJ, van Gilst WH. The current role of ACE inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice. Cardiovasc Drugs Ther 2006;20:69-73
18. Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol 2007;121:57-61
19. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Effects of angiotensin-converting enzyme (ACE) inhibition on rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21 DOI 10.1007/s10557-007-6068-5
20. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;16:149-60
21. Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor and nitric oxide synthase expression in patients with coronary artery disease. Hypertension 2002;39:634-8
22. Oosterga M, Voors AA, Buikema H, et al. on behalf of the QUO VADIS Investigators. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. Cardiovasc Drugs Ther 2000;14:55-60
23. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007 (in press)
24. Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999;34:700-10
25. Kim YM, Talanian RV, Billiar TR. Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem 1998;273:31437-41
26. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;274:17325-33